1. Summary of adverse events for LZV versus placebo and RZV versus placebo.

Comparison	Summary of adverse events
LZV versus placebo	The incidence of the following AEs did not differ significantly between the groups receiving LZV or placebo: 1 or more SAEs (including death), vaccine‐related SAEs, systemic AEs, AEs not related to vaccine, and haematoma at inoculation site. Participants of the vaccinated group had a higher incidence of vaccine‐related AEs and vaccine‐related systemic AEs beyond AEs at the injection site (erythema, pain, swelling, warmth, pruritus, rash, mass, and varicella‐like rash). The injection site AEs were erythema, pruritus, swelling, which lasted longer in the LZV group, and duration of rash lasted longer in the placebo group.
RZV versus placebo	The incidence of the following AEs did not differ significantly between the groups receiving RZV or placebo: SAEs (including death), SAEs (including death) related to vaccination, and potential immune‐mediated disease. Systemic AEs (myalgia, fatigue, headache, fever, shivering, and gastrointestinal symptom) as well as local AEs (redness, pain, and swelling) occurred more frequently in the RZV group than in the placebo group.

AEs: adverse events
 LZV: live zoster vaccine
 RZV: recombinant zoster vaccine
 SAEs: serious adverse events